206 related articles for article (PubMed ID: 21358346)
1. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
[TBL] [Abstract][Full Text] [Related]
2. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
4. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Hollevoet K; Nackaerts K; Thas O; Thimpont J; Germonpré P; De Vuyst P; Bosquée L; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Chest; 2012 Feb; 141(2):477-484. PubMed ID: 21737491
[TBL] [Abstract][Full Text] [Related]
5. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
7. Validity of mesothelin in occupational medicine practice.
Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
[TBL] [Abstract][Full Text] [Related]
9. Current status of screening for malignant pleural mesothelioma.
Pass HI; Carbone M
Semin Thorac Cardiovasc Surg; 2009; 21(2):97-104. PubMed ID: 19822280
[TBL] [Abstract][Full Text] [Related]
10. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
11. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
12. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
13. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR
Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574
[TBL] [Abstract][Full Text] [Related]
14. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
15. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
[TBL] [Abstract][Full Text] [Related]
17. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
19. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
Creaney J; Musk AW; Robinson BW
J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
